A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patients with Juvenile Idiopathic Arthritis (JIA) in clinical remission

Submission date	Recruitment status	Prospectively registered		
26/11/2005	No longer recruiting	☐ Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
16/02/2006		[X] Results		
Last Edited	Condition category	Individual participant data		
08/04/2010	Musculoskeletal Diseases			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Dirk Foell

Contact details

University Hospital Muenster Department of Pediatrics Albert-Schweitzer-Str. 33 Muenster Germany 48149 +49 (0)251 8356584 dfoell@uni-muenster.de

Additional identifiers

Protocol serial number 2005-001086-34

Study information

Scientific Title

Acronym

MTX-withdrawal-study

Study objectives

Treatment with the disease modifying anti-rheumatic drug (DMARD) methotrexate (MTX) in doses of 10 to 15 mg/m² given once weekly has been proven to be safe and effective in JIA. With this regime it is possible to attain relieve of clinical symptoms and normalisation of laboratory parameters in a number of cases. In contrast to the situation in adulthood, clinical remission on and off medication in JIA is possible. Therefore, it has been reported that discontinuation of MTX should be considered after an adequate period of remission.

About 50% of the patients experience a relapse after discontinuation of the immunosuppressive therapy. It is not yet clear if a longer duration of MTX treatment in the status of remission is able to reduce the overall risk of relapses over the course of the disease. Thus, treatment with MTX is continued for a variable time span after documentation of remission and according to the personal beliefs of the attending physicians.

Recently a definition of clinical remission for JIA has been proposed based on clinical examination and laboratory parameters. We also demonstrated that analyses of the phagocyte-specific proteins myeloid related-protein 8 (MRP 8) and MRP 14 provide excellent markers for the disease activity of JIA.

The present study was designed for the follow-up of two groups of patients with JIA, in whom remission was achieved using MTX. In group 1, treatment with MTX will be discontinued as early as six months after documentation of remission on medication. In group 2, treatment with MTX will be discontinued later than 12 months after documentation of remission on medication.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Committee at the University of Muenster, reference number 0VIIIRot

Study design

Prospective, randomised, clinical multi-centre study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Juvenila Idiopathic Arthritis (JIA)

Interventions

The study is designed as a prospective, randomised clinical trial with follow up documentation of 2 groups of patients.

Group 1:

At three months: first confirmation of remission on medication on the basis of signs of disease activity (no joints with active arthritis, no fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, no active uveitis, no elevation in ESR and/or CRP attributable to JIA; physicians global assessment of disease activity indicates no disease activity). At this point only on a combination of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), low-dose steroids (0.2 mg/kg per day or 10 mg per day whichever is lower), and MTX (max 15 mg/m^2 per week) is allowed, all the other drugs (e.g. biologics, intra-articular joint injections) must have been withdrawn before this date according to the physician decision. During the following three months low dose steroids and NSAIDS must be withdrawn according to the attending physician decision.

Time point zero months treatment with MTX is continued with dose range of 10 to 15 mg/m² per week (by oral, subcutaneous, intra-muscular or intravenous admission) after this time point. One NSAID is allowed.

Time point three months documentation of the clinical course after three months in remission. 6 months later confirmation of remission, discontinuation of MTX (and NSAID if applicable).

In further follow up examinations in intervals of three months the clinical course is documented over at least one year.

Group 2:

At time three months: first confirmation of remission on medication on the basis of signs of disease activity (no joints with active arthritis, fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, no active uveitis, no elevation in ESR and/or CRP attributable to JIA, physicians global assessment of disease activity indicates no disease activity). At this point only on a combination of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), low-dose steroids (0.2 mg/kg per day or 10 mg per day whichever is lower), and MTX (max 15 mg/m^2 per week) is allowed, all the other drugs (e.g. biologics, intra-articular joint injections) must have been withdrawn before this date according to the physician decision. During the following three months, low dose steroids and NSAIDs must be withdrawn according to the attending physician decision.

Time point zero months treatment with MTX is continued with dose range of 10-15 mg/m^2 per week (by oral, subcutaneous, intra-muscular or intravenous admission) after this time point. One NSAID is allowed.

Time point three months - documentation of the clinical course after three months in remission. Time point six months - documentation of the clinical course after six months in remission. Time point nine months - documentation of the clinical course after nine months in remission. Twelve months later (time point 12) - approval of remission, discontinuation of MTX (and NSAID if applicable).

In further follow up examinations in intervals of three months, the clinical course is documented over at least one year.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Methotrexate (MTX)

Primary outcome(s)

Number of relapses

Key secondary outcome(s))

- 1. Time to relapse
- 2. Prediction of relapse by MRP8 or MRP14 serum concentrations

Completion date

31/12/2008

Eligibility

Key inclusion criteria

Patients will be included at first confirmation of remission on medication i.e. after clinically documented inactive disease for at least three months (no joints with active arthritis, no fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA, no active uveitis, no elevation in Erythrocyte Sedimentation Rate [ESR] and/or C-Reactive Protein [CRP] attributable to JIA, physicians global assessment of disease activity indicates no disease activity).

At three months, patients may be only be on a combination of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), low-dose steroids (0.2 mg/kg per day or 10 mg per day whichever is lower), and MTX (max 15 mg/m^2 per week); all the other drugs (e.g. biologics) must have been withdrawn before this date according to the physicians decision.

Before inclusion into this study (study time point 0 months), patients will be considered to be in clinically documented remission on medication. At this time point, all medications other than NSAIDs and MTX with a dose range of 10 to 15 mg/m² per week have to be withdrawn. After discontinuation of MTX (study time point 6 i.e. after 6 months in group 1; study time point 12 i.e. after 12 months in group 2) treatment with NSAIDs should be stopped.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Αll

Key exclusion criteria

Patients should not have received intra-articular corticosteroids up to three months prior to inclusion

Date of first enrolment

01/01/2005

Date of final enrolment 31/12/2008

Locations

Locations				
Countries of recruitment United Kingdom				
Argentina				
Brazil				
Chile				
Croatia				
Cuba				
Czech Republic				
Denmark				
Finland				
France				
Georgia				
Germany				
Greece				
Hungary				
India				
Israel				
Italy				
Kuwait				
Latvia				
Mexico				
Montenegro				

Netherlands

Poland
Portugal
Romania
Russian Federation
Saudi Arabia
Serbia
Slovakia
Spain
Switzerland
Гürkiye
Study participating centre University Hospital Muenster Muenster Germany 18149
Sponsor information
Organisation Pediatric Rheumatology International Trials Organisation (PRINTO) (Italy) and Wyeth Pharma
Funder(s)
Funder type Research organisation
Funder Name Pediatric Rheumatology International Trials Organisation (PRINTO) (EU grant number 2001CVG4- 308)

Funder Name

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	07/04/2010		Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes